Repare Therapeutics Inc (NASDAQ: RPTX)宣布与生物制药企业Debiopharm达成突破性合作。根据协议条款，Repare将授予后者抗癌药物Lunresertib的全球独家开发及商业化权利。
该交易包含显著的经济价值：Repare将立即获得1000万美元首付款，并有资格获取最高达2.57亿美元的里程碑款项。值得关注的是，里程碑金额涵盖药物开发、监管审批及商业化各阶段的成就奖励。
作为协议核心内容，Debiopharm将全面主导关键性MYTHIC临床研究的推进工作，承担Lunresertib后续全球开发计划。此项安排使Repare能够将资源集中于核心管线，同时通过阶段性收益优化资金使用效率。
Lunresertib作为精准抗癌疗法，其独特的作用机制在早期临床研究中展现出克服肿瘤耐药性的潜力。此次战略合作印证了该候选药物的商业价值，也为后续适应症拓展奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.